D.E. Shaw & Co
KIN

D.E. Shaw & Co’s Kindred Biosciences, Inc. KIN Stock Holding History

D.E. Shaw & Co’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-23,443
Closed -$327K – 4099
2018
Q3 		$327K Buy
+23,443
New +$317K ﹤0.01% 3320
2018
Q2 		– Sell
-13,163
Closed -$114K – 3965
2018
Q1 		$114K Sell
13,163
-5,970
-31% -$52.4K ﹤0.01% 3383
2017
Q4 		$181K Sell
19,133
-4,063
-18% -$31.7K ﹤0.01% 3445
2017
Q3 		$182K Buy
+23,196
New +$174K ﹤0.01% 3319

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co's KIN Position: Q4 2018 in Review

D.E. Shaw & Co sold out of Kindred Biosciences, Inc. (KIN) in Q4 2018, closing a stake of 23,443 shares — an estimated $327K sold.

D.E. Shaw & Co first reported a position in KIN in Q3 2017 and held it in 4 quarters. The position peaked at $327K in Q3 2018. 72 funds tracked by Wall St. Rank hold KIN as of Q4 2018.

  • D.E. Shaw & Co reported no remaining Kindred Biosciences, Inc. position as of Q4 2018 after selling out during the quarter.
  • D.E. Shaw & Co sold 23,443 Kindred Biosciences, Inc. shares in Q4 2018, an estimated $327K.
  • D.E. Shaw & Co first reported a position in Kindred Biosciences, Inc. in Q3 2017 and held it in 4 quarters.
  • D.E. Shaw & Co's Kindred Biosciences, Inc. position peaked at $327K in Q3 2018.
  • 72 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q4 2018.

Based on D.E. Shaw & Co's 13F filing for Q4 2018, filed 14 Feb 2019.